Advisory Services Network LLC Decreases Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Advisory Services Network LLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,773 shares of the medical research company’s stock after selling 354 shares during the quarter. Advisory Services Network LLC’s holdings in Charles River Laboratories International were worth $512,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International during the 4th quarter valued at approximately $48,000. Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the last quarter. Finally, Huntington National Bank lifted its stake in shares of Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock worth $55,000 after buying an additional 164 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.5 %

Shares of CRL opened at $106.02 on Wednesday. The firm’s fifty day moving average is $154.31 and its two-hundred day moving average is $175.73. The stock has a market cap of $5.21 billion, a PE ratio of 706.79, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the business posted $2.46 earnings per share. The firm’s revenue was down 1.1% compared to the same quarter last year. Research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Morgan Stanley dropped their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Barclays reduced their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Finally, Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $182.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).